Advanced search
Publication Cover
Biomarkers in Medicine Volume 5, 2011 - Issue 3
Submit an article Journal homepage
206
Views
0
CrossRef citations to date
0
Altmetric
Review

Biomarker-Based Selection of Therapy For Colorectal Cancer

Jeffrey S RossFoundation Medicine Inc.,Cambridge,MA,USA and Department of Pathology & Laboratory Medicine,Albany Medical College,Department of Pathology,Mail Code 81, 47 New Scotland Avenue,Albany,NY 12208,USA. Correspondence[email protected]
Pages 319-332 | Published online: 09 Jun 2011

Bibliography

  • Jemal A , SiegelR, WardEet al. : Cancer statistics.CA Cancer J. Clin.59, 225–249 (2009).
  • Treanor D , QuirkeP: Pathology of colorectal cancer.Clin. Oncol.19, 769–776 (2007).
  • Hamilton SR : Targeted therapy of cancer: new roles for pathologists in colorectal cancer.Mod. Pathol.21(Suppl. 2), 23–30 (2008).
  • Kinzler KW , VogelsteinB: Colorectal tumors. In: The Genetic Basis of Human Cancer. (2nd Edition). VogelsteinB, KinzlerKW (Eds). McGraw-Hill, NY, USA, 583–612 (2002).
  • Libutti SK , SaltzLB, TepperJE: Colon cancer. In: DeVita, Hellman, and Rosenberg‘s Cancer: Principles and Practice of Oncology. DeVitaVT Jr, LawrenceTS, RosenbergSA (Eds). Lippincott Williams & Wilkins, PA, USA, 1232–1284 (2008).
  • Markowitz SD , BertagnolliMM: Molecular origins of cancer: molecular basis of colorectal cancer.N. Engl. J. Med.361, 2449–2460 (2009).
  • Gryfe R : Overview of colorectal cancer genetics.Surg. Oncol. Clin. N. Am.18, 573–583 (2009).
  • Fakih M : The role of targeted therapy in the treatment of advanced colorectal cancer.Curr. Treat. Options Oncol.9, 357–374 (2008).
  • Hegde SR , SunW, LynchJP: Systemic and targeted therapy for advanced colon cancer.Expert Rev. Gastroenterol. Hepatol.2, 135–149 (2008).
  • Ortega J , VigilCE, ChodkiewiczC: Current progress in targeted therapy for colorectal cancer.Cancer Control17, 7–15 (2010).
  • Walther A , JohnstoneE, SwantonCet al. : Genetic prognostic and predictive markers in colorectal cancer.Nat. Rev. Cancer9, 489–499 (2009).
  • Stewart CJ , HilleryS, PlattellC: Protocol for the examination of specimens from patients with primary carcinomas of the colon and rectum.Arch. Pathol. Lab. Med.133, 1359–1360 (2009).
  • Kim J , HuynhR, AbrahamIet al. : Number of lymph nodes examined and its impact on colorectal cancer staging.Am. Surg.72, 902–905 (2006).
  • Compton CC : Optimal pathologic staging: defining stage II disease.Clin. Cancer Res.13, 6862s–6870s (2007).
  • Bembenek A , StringA, GretschelS,Schlag PM: Technique and clinical consequences of sentinel lymph node biopsy in colorectal cancer. Surg. Oncol.17, 183–193 (2008).
  • Bilchik AJ , NoraDT, SahaSet al. : The use of molecular profiling of early colorectal cancer to predict micrometastases.Arch. Surg.137, 1377–1383 (2002).
  • Kelder W , BraatA, van den BergAet al.: Value of RT-PCR analysis of sentinel nodes in determining the pathological nodal status in colon cancer.Anticancer Res.27, 2855–2859 (2007).
  • Zhang D , BaiY, GeQet al. : Microarray-based molecular margin methylation pattern analysis in colorectal carcinoma.Anal. Biochem.355, 117–124 (2006).
  • Ross JS , HatzisC, SymmansWFet al. : Commercialized multigene predictors of clinical outcome for breast cancer.Oncologist13, 477–493 (2008).
  • Gray R , BarnwellJ, McConkeyC, HillsRK, WilliamsNS, KerrDJ: Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.Lancet5(370), 2020–2029 (2007).
  • Kerr D , GrayR, QuirkePet al. : A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study.J. Clin. Oncol.27, Suppl. 15 (2009) (abstract 4000).
  • Glas AM , RoepmanP, SalazarRet al. : Development and validation of a robust prognostic and predictive signature for colorectal cancer (CRC) patients.J. Clin. Oncol.27, Suppl. 15 (2009) (abstract 4036).
  • Ross JS , SlodkowskaEA: Circulating and disseminated tumor cells in the management of breast cancer.Am. J. Clin. Pathol.132, 237–245 (2009).
  • Rahbari NN , AignerM, ThorlundKet al. : Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer.Gastroenterology138(5), 1714–1726 (2010).
  • Tsouma A , AggeliC, PissimissisNet al. : Circulating tumor cells in colorectal cancer: detection methods and clinical significance.Anticancer Res.28, 3945–3960 (2008).
  • Cohen SJ , PuntCJ, IannottiNet al. : Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer.Ann. Oncol.20(7), 1223–1229 (2009).
  • Maestro LM , SastreJ, RafaelSBet al. : Circulating tumor cells in solid tumor in metastatic and localized stages.Anticancer Res.29(11), 4839–4843 (2009).
  • Wong SC , ChanCM, MaBBet al. : Clinical significance of cytokeratin 20-positive circulating tumor cells detected by a refined immunomagnetic enrichment assay in colorectal cancer patients.Clin. Cancer Res.15(3), 1005–1012 (2009).
  • Vilar E , GruberSB: Microsatellite instability in colorectal cancer-the stable evidence.Nat. Rev. Clin. Oncol.7(3), 153–162 (2010).
  • de la Chapelle A , HampelH: Clinical relevance of microsatellite instability in colorectal cancer.J. Clin. Oncol.28(20), 3380–3387 (2010).
  • Sanoff HK , SargentDJ, GreenEM, McLeodHL, GoldbergRM: Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial.J. Clin. Oncol.27(25), 4109–4115 (2009).
  • Neal CP , GarceaG, DoucasHet al. : Molecular prognostic markers in resectable colorectal liver metastases: a systematic review.Eur. J. Cancer42, 1728–1743 (2006).
  • Koopman M , VenderboschS, NagtegaalIDet al. : A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?Eur. J. Cancer45, 1935–1949 (2009).
  • Zlobec I , LugliA: Prognostic and predictive factors in colorectal cancer.Postgrad. Med. J.84, 403–411 (2008).
  • Shankaran V , WisinskiKB, MulcahyMFet al. : The role of molecular markers in predicting response to therapy in patients with colorectal cancer.Mol. Diagn. Ther.12, 87–98 (2008).
  • Zlobec I , LugliA: Prognostic and predictive factors in colorectal cancer.J. Clin. Pathol.61, 561–569 (2008).
  • Walther A , JohnstoneE, SwantonCet al. : Genetic prognostic and predictive markers in colorectal cancer.Nat. Rev. Cancer9, 489–499 (2009).
  • Ogino S , NoshoK, KirknerGJet al. : PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.J. Clin. Oncol.27, 1477–1484 (2009).
  • Roth AD , TejparS, DelorenziMet al. : Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60–00 trial.J. Clin. Oncol.28, 466–474 (2010).
  • Compton CC , FieldingLP, BurgartLJet al. : Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999.Arch. Pathol. Lab. Med.124, 979–994 (2000).
  • Locker GY , HamiltonS, HarrisJet al. : ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.J. Clin. Oncol.24, 5313–5327 (2006).
  • Vincenzi B , ZoccoliA, PantanoFet al. : Cetuximab: from bench to bedside.Curr. Cancer Drug Targets10(1), 80–95 (2010).
  • Giusti RM , CohenMH, KeeganPet al. : FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer.Oncologist14, 284–290 (2009).
  • Bardelli A , SienaS: Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.J. Clin. Oncol.28(7), 1254–1261 (2010).
  • Monzon FA , OginoS, HammondMEet al. : The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer.Arch. Pathol. Lab. Med.133, 1600–1606 (2009).
  • Plesec TP , HuntJL: KRAS mutation testing in colorectal cancer.Adv. Anat. Pathol.16, 196–203 (2009).
  • Jimeno A , MessersmithWA, HirschFRet al. : KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection.J. Clin. Oncol.27, 1130–1136 (2009).
  • Modjtahedi H , EssapenS: Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.Anticancer Drugs20, 851–855 (2009).
  • Nie F , ShenJ, TongJLet al. : Meta-analysis: the efficacy and safety of monoclonal antibody targeted to epidermal growth factor receptor in the treatment of patients with metastatic colorectal cancer.J. Dig. Dis.10, 247–257 (2009).
  • Amado RG , WolfM, PeetersMet al. : Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.J. Clin. Oncol.26, 1626–1634 (2008).
  • Bokemeyer C , BondarenkoI, MakhsonAet al. : Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.J. Clin. Oncol.27, 663–671 (2009).
  • Van Cutsem E , KöhneCH, HitreEet al. : Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.N. Engl. J. Med.360, 1408–1417 (2009).
  • Loupakis F , RuzzoA, CremoliniCet al. : KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.Br. J. Cancer101, 715–721 (2009).
  • De Roock W , ClaesB, BernasconiDet al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 11(8), 753–762 (2010).
  • Fadhil W , IbrahemS, SethRet al. : Quick-multiplex-consensus (QMC)-PCR followed by high-resolution melting: a simple and robust method for mutation detection in formalin-fixed paraffin-embedded tissue.J. Clin. Pathol.63, 134–140 (2010).
  • Franklin WA , HaneyJ, SugitaMet al. : KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer.J. Mol. Diagn.12, 43–50 (2010).
  • Di Nicolantonio F , MartiniM, MolinariFet al. : Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.J. Clin. Oncol.26, 5705–5712 (2008).
  • Tran B , KopetzS, TieJet al. : Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer.Cancer (2011) (Epub ahead of print).
  • Rizzo S , BronteG, FanaleDet al. : Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild-type status required for anti-EGFR therapy?Cancer Treat Rev.36(Suppl. 3), S56–S61 (2010).
  • Souglakos J , PhilipsJ, WangRet al. : Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.Br. J. Cancer101, 465–472 (2009).
  • Sartore-Bianchi A , Di NicolantonioF, NichelattiMet al.: Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.PLoS One4, e7287 (2009).
  • Sartore-Bianchi A , MartiniM, MolinariFet al. : PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.Cancer Res.69, 1851–1857 (2009).
  • Jhawer M , GoelS, WilsonAJet al. : PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.Cancer Res.68(6), 1953–1961 (2008).
  • Prenen H , De Schutter J, Jacobs B et al.: PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin. Cancer Res.15, 3184–3188 (2009).
  • Perrone F , LampisA, OrsenigoMet al. : PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.Ann. Oncol.20, 84–90 (2009).
  • Oden-Gangloff A , Di Fiore F, Bibeau F et al.: TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. Br. J. Cancer100, 1330–1335 (2009).
  • Laurent-Puig P , CayreA, ManceauGet al. : Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.J. Clin. Oncol.27, 5924–5930 (2009).
  • Iannello A , AhmadA: Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies.Cancer Metastasis Rev.24, 487–499 (2005).
  • Winder T , ZhangW, YangDet al. : Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients.Clin. Cancer Res.16(22), 5591–5602 (2010).
  • Jacobs B , De RoockW, PiessevauxHet al.: Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.J. Clin. Oncol.27(30), 5068–5074 (2009).
  • Saridaki Z , TzardiM, PapadakiCet al. : Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients.PLoS One6(1), e15980 (2011).
  • Zhang W , GordonM, SchultheisAMet al. : FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.J. Clin. Oncol.25, 3712–3718 (2007).
  • Bibeau F , Lopez-CrapezE, Di FioreFet al.: Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.J. Clin. Oncol.27, 1122–1129 (2009).
  • Hsu JY , WakeleeHA: Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.BioDrugs23, 289–304 (2009).
  • Loupakis F , BocciG, PasqualettiGet al. : Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients.Curr. Cancer Drug Targets10(1), 37–45 (2010).
  • Welch S , SpithoffK, RumbleRB,Maroun J; The Gastrointestinal Cancer Disease Site Group: Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann. Oncol.21(6), 1152–1162 (2009).
  • Grothey A , SargentD, GoldbergRMet al. : Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.J. Clin. Oncol.22, 1209–1214 (2004).
  • Lurje G , ManegoldPC, NingYet al. : Thymidylate synthase gene variations: predictive and prognostic markers.Mol. Cancer Ther.8(5), 1000–1007 (2009).
  • Popat S , MatakidouA, HoulstonRS: Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis.J. Clin. Oncol.22, 529–536 (2004).
  • Shirota Y , StoehlmacherJ, BrabenderJet al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol. 19(23), 4298–4304 (2001).
  • Schmoll HJ : Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer.Anticancer Drugs14, 695–702 (2003).
  • van Kuilenburg AB : Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.Eur. J. Cancer40, 939–950 (2004).
  • Zintzaras E , ZiogasDC, KitsiosGDet al. : MTHFR gene polymorphisms and response to chemotherapy in colorectal cancer: a meta-analysis.Pharmacogenomics10, 1285–1294 (2009).
  • Braun MS , RichmanSD, ThompsonLet al. : Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.J. Clin. Oncol.27, 5519–5528 (2009).
  • Etienne-Grimaldi MC , MilanoG, Maindrault-GoebelFet al. : Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.Br. J. Clin. Pharmacol.69, 58–66 (2010).
  • Ezzeldin HH , DiasioRB: Predicting fluorouracil toxicity: can we finally do it?J. Clin. Oncol.26, 2080–2082 (2008).
  • Wolpin BM , MayerRJ: Systemic treatment of colorectal cancer.Gastroenterology134, 1296–1310 (2008).
  • Weekes J , LamAK, SebesanS, HoYH: Irinotecan therapy and molecular targets in colorectal cancer: a systemic review.World J. Gastroenterol.15, 3597–3602 (2009).
  • Montagnani F , ChiriattiA, TurrisiGet al. : A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity.Colorectal Dis. DOI: 10.1111/j.1463-1318.2010.02206.x (2010) (Epub ahead of print).
  • Kostopoulos I , KaravasilisV, KarinaMet al. : Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy.BMC Cancer9, 339 (2009).
  • Braun MS , RichmanSD, QuirkePet al. : Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial.J. Clin. Oncol.26, 2690–2698 (2008).
  • Schulz C , BoeckS, HeinemannVet al. : UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?Anticancer Drugs20(10), 867–879 (2009).
  • Palomaki GE , BradleyLA, DouglasMPet al. : Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review.Genet. Med.11, 21–34 (2009).
  • Braun MS , RichmanSD, ThompsonLet al. : Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.J. Clin. Oncol.27, 5519–5528 (2009).
  • S⊘rensen NM , ByströmP, ChristensenIJet al. : TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid.Clin. Cancer Res.13, 4117–4122 (2007).
  • Bendardaf R , LamlumH, RistamäkiRet al. : CD44 variant 6 expression predicts response to treatment in advanced colorectal cancer.Oncol. Rep.11, 41–45 (2004).
  • Capdevila J , ElezE, PeraltaSet al. : Oxaliplatin-based chemotherapy in the management of colorectal cancer.Expert Rev. Anticancer Ther.8, 1223–1236 (2008).
  • Shah N , DizonDS: New-generation platinum agents for solid tumors.Future Oncol.5, 33–42 (2009).
  • Fogelman DR , KopetzS, EngC: Emerging drugs for colorectal cancer.Expert Opin. Emerg. Drugs13, 629–642 (2008).
  • Kim SH , KwonHC, OhSYet al. : Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase π for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.Am. J. Clin. Oncol.32, 38–43 (2009).
  • Yeh CS , WangJY, ChungFYet al. : Significance of the glycolytic pathway and glycolysis related-genes in tumorigenesis of human colorectal cancers.Oncol. Rep.19(1), 81–91 (2008).
  • Olaussen KA , FouretP, KroemerG: ERCC1-specific immunostaining in non-small-cell lung cancer.N. Engl. J. Med.357, 1559–1561 (2007).
  • Liang J , JiangT, YaoRYet al. : The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.Cancer Chemother. Pharmacol.66(3), 493–500 (2009).
  • Chua W , GoldsteinD, LeeCKet al. : Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.Br. J. Cancer101, 998–1004 (2009).
  • Paré L , MarcuelloE, AltésAet al. : Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy.Br. J. Cancer99, 1050–1055 (2008).
  • Stoehlmacher J , ParkDJ, ZhangWet al. : A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.Br. J. Cancer91, 344–354 (2004).
  • Monzo M , MorenoI, NavarroAet al. : Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.Oncology72, 364–370 (2007).
  • Lai JI , TzengCH, ChenPMet al. : Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma.Cancer Sci.100, 1261–1266 (2009).
  • Liu X , ZhouB, XueLet al. : Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer.Clin. Colorectal Cancer6, 374–381 (2007).
  • Chua W , GoldsteinD, LeeCKet al. : Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.Br. J. Cancer101, 998–1004 (2009).
  • Suh KW , KimJH, Kim do Y et al.: Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene? Ann. Surg. Oncol.13, 1379–1385 (2006).
  • Stoehlmacher J , GhaderiV, IobalSet al. : A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer.Anticancer Res.21, 3075–3079 (2001).
  • Gurubhagavatula S , LiuG, ParkSet al. : XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.J. Clin. Oncol.22, 2594–2601 (2004).
  • Funke S , TimofeevaM, RischAet al. : Genetic polymorphisms in GST genes and survival of colorectal cancer patients treated with chemotherapy.Pharmacogenomics11, 33–41 (2010).
  • Kweekel DM , GelderblomH, AntoniniNFet al. : Glutathione-S-transferase π (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients.Eur. J. Cancer45, 572–578 (2009).
  • Lecomte T , LandiB, BeaunePet al. : Glutathione S-transferase π1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy.Clin. Cancer Res.12, 3050–3056 (2006).
  • Iwatsuki M , MimoriK, YokoboriTet al. : A platinum agent resistance gene, POLB, is a prognostic indicator in colorectal cancer.J. Surg. Oncol.100, 261–266 (2009).
  • O‘Connell MJ : Oxaliplatin or irinotecan as adjuvant therapy for colon cancer: the results are in.J. Clin. Oncol.27, 3082–3084 (2009).
  • Lenz HJ : Pharmacogenomics and colorectal cancer.Adv. Exp. Med. Biol.587, 211–231 (2006).
  • Rodriguez J , ZarateR, BandresEet al. : Combining chemotherapy and targeted therapies in metastatic colorectal cancer.World J. Gastroenterol.13, 5867–5876 (2007).
  • Ross JS , Torres-MoraJ, WagleN, JenningsTA, JonesDM: Biomarker-based prediction of response to therapy for colorectal cancer: current perspective.Am. J. Clin. Pathol.134, 478–490 (2010).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.